Elon Musk’s Neuralink successfully implants first chip in human brain

Elon Musk's controversial startup signals progress in bridging human-machine interface
Elon Musk’s Neuralink successfully implants first chip in human brain
Musk unveiled that Neuralink's maiden product would be named Telepathy

In a bold move that could revolutionize the field of neurotechnology, Elon Musk’s startup, Neuralink, announced the successful implantation of a chip in a human brain. Musk shared this groundbreaking development on his X platform, revealing that the operation occurred on Sunday, with the patient already in the recovery phase.

Unveiling the breakthrough

Elon Musk’s announcement represents a pivotal moment for Neuralink, marking a significant step toward translating their potentially life-transforming technology from the laboratory into practical applications. However, details provided in Musk’s post remain sparse, leaving the scientific community and the public intrigued about the true magnitude of this achievement.

Neuralink’s endeavor was not without regulatory oversight. The company obtained approval to conduct a study on the safety and functionality of its chip implant and surgical tools. Musk shared initial results, expressing optimism about promising neuron spike detection.

Neuralink’s first product

In a subsequent post, Musk unveiled that Neuralink’s maiden product would be named Telepathy. He emphasized that the initial users of this revolutionary technology would be individuals who had lost the use of their limbs. Hence, Musk envisioned a future where people, like Stephen Hawking, could communicate faster and better.

Neuralink has been on a five-year journey to establish brain-computer interfaces, facing acclaim and scrutiny. The company came under fire in 2022 when a monkey died during an attempt to play Pong. This led to several federal investigations. Therefore, Musk’s recent announcement comes after the company received FDA clearance for human clinical trials in May of 2023.

The PRIME study

Neuralink’s clinical trials, known as the PRIME Study (Precise Robotically Implanted Brain-Computer Interface), aim to assess the safety of the implant and surgical robot while testing the device’s functionality. Patients in the trial, suffering from quadriplegia due to spinal cord injury or ALS, will have a chip placed in the brain’s intention control center. This chip, installed by a robot, will record and transmit brain signals to an app. The initial goal is to allow individuals to control a computer cursor or keyboard through thoughts alone.

Regulatory hurdles

Before Neuralink’s brain implants can reach the broader market, regulatory approval is imperative. The FDA released a paper in 2021 outlining its initial thoughts on brain-computer interface devices, recognizing the rapid progression of this field. However, Musk’s company is not the only player in this arena. Synchron, a company that gained FDA clearance in 2021, has been actively enrolling and implanting patients in a similar trial.

Read: Robots enable UAE ministry of finance to achieve 98 percent accuracy, save 39,000 hours

Future prospects

Neuralink and Musk have captured significant attention for their pursuit of a brain-computer interface. However, other companies including Synchron, are contributing to the evolving landscape of neurotechnology. Scientists acknowledged the potential of brain-nervous system interfaces to aid those with neurological disorders. However, they highlighted the experimental nature and the necessity for invasive neurosurgery, suggesting that widespread availability may still be years away.

Therefore, Neuralink’s recent achievement is undeniably a giant leap forward in the realm of brain-machine interfaces. However, the road ahead involves navigating regulatory challenges. Moreover, addressing concerns surrounding the experimental nature of such technology is crucial. As these ventures continue to unfold, they hold the promise of transformative breakthroughs that could reshape the lives of individuals with neurological disorders.

For more news on technology, click here.

The stories on our website are intended for informational purposes only. Those with finance, investment, tax or legal content are not to be taken as financial advice or recommendation. Refer to our full disclaimer policy here.